We explain what is behind DiLumen and where we intend to go with it.
The newsletter contains information about the milestones reached during 2015. It also discusses the plans we have for 2016.
Die Lumendi Ltd. hat einen Newsletter bereitgestellt.
Mehr Details gibt es im Blogeintrag inklusive die Möglichkeit zum Download der PDF Datei.
Mike Parrilla comes with a proven track record.
Right now, Mike’s main focus is on getting Lumendi’s endoluminal device for minimally-invasive gastrointestinal surgery FDA approved.
Lumendi LLC USA bezieht ihre Büros.
Growth means you have to get your offices expanded. Lumendi AG has established a subsidiary in the USA.
Here we tell you more about where they are and who its Chief Operating Officer (COO) is.
Daran denken (Please do not forget) unseren Newsletter abonnieren (subscribe to our newsletter). Mehr (more) …!
Last week it became official:
– Weill Cornell Medical College,
– NewYork-Presbyterian Hospital, and their
– Minimally Invasive New Technologies Program (MINT) have teamed up with
– Lumendi Ltd.
You can view and / or download additional material in the post.
Don’t forget: Subscribe to our blog’s newsletter!
This week, much of Europe enjoyed a heatwave. We held another informational event for potential investors.
Here we we spell out how it went, share some visual tidbits and so forth.
You can view and / or download some material as well.